Grace Therapeutics Q3 net loss $4.2M; Phase 3 STRIVE-ON meets endpoint; $15M placement

Grace Therapeutics, Inc.

2025-Q3 EPS reported -$0.89 vs consensus -$0.19 ▼ miss (-371.6%)

Net loss $4.2M ($0.36/sh) vs $2.4M ($0.21/sh) YoY; R&D $2.2M up from $1.4M on GTx-104 trial.
Phase 3 STRIVE-ON safety trial met primary endpoint; NDA for GTx-104 anticipated H1 2025.
Secured $15M upfront private placement (Nantahala Capital, ADAR1, Stonepine); up to $15M additional from warrant exercises.
Cash at Dec 31, 2024: $11.1M, down from $23.0M at Mar 31, 2024.
FDA provided guidance on single pivotal trial design for GTx-102 (Ataxia-Telangiectasia) toward NDA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.